Autres langues Corvus Pharmaceuticals, Inc.

Actions

CRVS

US2210151005

Temps réel estimé Cboe BZX Autres places de cotation 20:26:28 10/06/2024			Varia. 5j.	Varia. 1 janv.
2,075 ^USD	+2,22 %		-5,66 %	+18,47 %

07/05	Un initié de Corvus Pharmaceuticals a acheté des actions pour une valeur de 1 000 000 $, selon un récent dépôt auprès de la SEC	MT
07/05	CORVUS PHARMACEUTICALS, INC. : Oppenheimer toujours positif	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference	30/05
Corvus Pharmaceuticals Insider Bought Shares Worth $1,000,000, According to a Recent SEC Filing	07/05
Corvus: Q1 Earnings Snapshot	06/05
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results	06/05
Corvus Pharmaceuticals, Inc. Provides Business Update	06/05
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	06/05
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024	02/05
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering	02/05
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings	30/04
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis	09/04
Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis	09/04
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	20/03
Corvus Pharmaceuticals to Start Phase 1 Study of Atopic Dermatitis Treatment in Q2	19/03
Corvus: Q4 Earnings Snapshot	19/03
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	19/03
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	19/03
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024	13/03
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases	12/02
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data At the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases	12/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Corvus Pharmaceuticals, Inc.

Actions

CRVS

US2210151005

Autres langues

Filtres